bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 7 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Authors: Dal Pra Alan , Lalonde Emilie , Sykes Jenna , Warde Fiona , Ishkanian Adrian , Meng Alice , Maloff Chad , Srigley John , Joshua Anthony M. , Petrovics Gyorgy , van der Kwast Theodorus , Evans Andrew , Milosevic Michael , Saad Fred , Collins Colin , Squire Jeremy , Lam Wan , Bismar Tarek A. , Boutros Paul C. , Bristow Robert G.
Published: April 2023

Supplementary Figure 7 - PDF file 106K, Univariate Kaplan-Meier plots of bRFR versus time to recurrence for the Memorial Sloan Kettering Prostate Cancer cohort of patients who underwent surgery with differential ERG status based on mRNA expression
Supplementary Figure 2 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Authors: Dal Pra Alan , Lalonde Emilie , Sykes Jenna , Warde Fiona , Ishkanian Adrian , Meng Alice , Maloff Chad , Srigley John , Joshua Anthony M. , Petrovics Gyorgy , van der Kwast Theodorus , Evans Andrew , Milosevic Michael , Saad Fred , Collins Colin , Squire Jeremy , Lam Wan , Bismar Tarek A. , Boutros Paul C. , Bristow Robert G.
Published: April 2023

Supplementary Figure 2 - PDF file 71K, Construction of biopsy TMA blocks. Four millimeter length of the needle biopsy core (previously delimited by pathologist) is cut out from the original formalin fixed paraffin embedded tissue block. A scalpel blade is used to cut the exceeding wax on the opposite side of the biopsy tissue (opposite side marked in green) in order to reach a final 4 mm x 2 mm x 2 mm checker. These checkers are flipped 90 degrees (long axis of the prostate needle biopsy turns vertical) and placed within a stainless steel mold as a TMA template. The TMA block is completed by re-embedding the checkers by pouring hot wax into the mold. Last step on the right side shows an Hematoxylin and Eosin (H-E)-stained section from a biopsy TMA block (low power)
CCR Translation for This Article from Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Authors: Eskens Ferry A.L.M. , Ramos Francisco J. , Burger Herman , O'Brien James P. , Piera Adelaida , de Jonge Maja J.A. , Mizui Yoshiharu , Wiemer Erik A.C. , Carreras Maria Josepa , Baselga José , Tabernero Josep
Published: April 2023

CCR Translation for This Article from Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Supplementary Figure 6 from Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer
Authors: Martens-de Kemp Sanne R. , Nagel Remco , Stigter-van Walsum Marijke , van der Meulen Ida H. , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file - 39K, Ispinesib treatment induces G2 arrest in HNSCC cell lines.
Supplementary Tables 1 - 3 from RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy
Authors: Rahman Mohammad Aminur , Amin A.R.M. Ruhul , Wang Dongsheng , Koenig Lydia , Nannapaneni Sreenivas , Chen Zhengjia , Wang Zhibo , Sica Gabriel , Deng Xingming , Chen Zhuo (Georgia) , Shin Dong M.
Published: April 2023

PDF file - 94K, Supplementary Table 1: Clinico-pathological features of the HNSCC and NSCLC patient groups. Supplementary Table 2: Average signal of RRM2 and Bcl-2 in tumor tissues from HNSCC patients. Supplementary Table 3: Average signal of RRM2 and Bcl-2 in tumor tissues from NSCLC patients.
Supplementary Figure 2 from Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer
Authors: Martens-de Kemp Sanne R. , Nagel Remco , Stigter-van Walsum Marijke , van der Meulen Ida H. , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file - 81K, Deconvolution of genes associated with mitotic spindle formation.
Supplementary Figure 9 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Authors: Chodon Thinle , Comin-Anduix Begoña , Chmielowski Bartosz , Koya Richard C. , Wu Zhongqi , Auerbach Martin , Ng Charles , Avramis Earl , Seja Elizabeth , Villanueva Arturo , McCannel Tara A. , Ishiyama Akira , Czernin Johannes , Radu Caius G. , Wang Xiaoyan , Gjertson David W. , Cochran Alistair J. , Cornetta Kenneth , Wong Deborah J.L. , Kaplan-Lefko Paula , Hamid Omid , Samlowski Wolfram , Cohen Peter A. , Daniels Gregory A. , Mukherji Bijay , Yang Lili , Zack Jerome A. , Kohn Donald B. , Heath James R. , Glaspy John A. , Witte Owen N. , Baltimore David , Economou James S. , Ribas Antoni
Published: April 2023

PDF file - 132KB, Recall whole body rash and re-expansion of the TCR transgenic cells in peripheral blood of patient F5-13 with subsequent MART-1/DC vaccination.
Supplementary Figure 8 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Authors: Chodon Thinle , Comin-Anduix Begoña , Chmielowski Bartosz , Koya Richard C. , Wu Zhongqi , Auerbach Martin , Ng Charles , Avramis Earl , Seja Elizabeth , Villanueva Arturo , McCannel Tara A. , Ishiyama Akira , Czernin Johannes , Radu Caius G. , Wang Xiaoyan , Gjertson David W. , Cochran Alistair J. , Cornetta Kenneth , Wong Deborah J.L. , Kaplan-Lefko Paula , Hamid Omid , Samlowski Wolfram , Cohen Peter A. , Daniels Gregory A. , Mukherji Bijay , Yang Lili , Zack Jerome A. , Kohn Donald B. , Heath James R. , Glaspy John A. , Witte Owen N. , Baltimore David , Economou James S. , Ribas Antoni
Published: April 2023

PDF file - 190KB, Cytokine production by multiplex assay in plasma from patients F5-12 and F5-14 to study the potential development of a cytokine storm.
Supplementary Figure 7 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Authors: Chodon Thinle , Comin-Anduix Begoña , Chmielowski Bartosz , Koya Richard C. , Wu Zhongqi , Auerbach Martin , Ng Charles , Avramis Earl , Seja Elizabeth , Villanueva Arturo , McCannel Tara A. , Ishiyama Akira , Czernin Johannes , Radu Caius G. , Wang Xiaoyan , Gjertson David W. , Cochran Alistair J. , Cornetta Kenneth , Wong Deborah J.L. , Kaplan-Lefko Paula , Hamid Omid , Samlowski Wolfram , Cohen Peter A. , Daniels Gregory A. , Mukherji Bijay , Yang Lili , Zack Jerome A. , Kohn Donald B. , Heath James R. , Glaspy John A. , Witte Owen N. , Baltimore David , Economou James S. , Ribas Antoni
Published: April 2023

PDF file - 470KB, Chest X-rays of patients F5-12 and 14 who developed SAEs of acute respiratory distress.
Supplementary Figure 6 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Authors: Chodon Thinle , Comin-Anduix Begoña , Chmielowski Bartosz , Koya Richard C. , Wu Zhongqi , Auerbach Martin , Ng Charles , Avramis Earl , Seja Elizabeth , Villanueva Arturo , McCannel Tara A. , Ishiyama Akira , Czernin Johannes , Radu Caius G. , Wang Xiaoyan , Gjertson David W. , Cochran Alistair J. , Cornetta Kenneth , Wong Deborah J.L. , Kaplan-Lefko Paula , Hamid Omid , Samlowski Wolfram , Cohen Peter A. , Daniels Gregory A. , Mukherji Bijay , Yang Lili , Zack Jerome A. , Kohn Donald B. , Heath James R. , Glaspy John A. , Witte Owen N. , Baltimore David , Economou James S. , Ribas Antoni
Published: April 2023

PDF file - 64KB, Comparison of IL-17 production by F5-10 infused TCR transgenic cells stimulated with MART-1-pulsed K562 A2.1 cells with that of patients who did not develop pancytopenia.
Supplementary Materials and Methods, Figure Legends, Table Legends from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets
Authors: Stefanska Barbara , Cheishvili David , Suderman Matthew , Arakelian Ani , Huang Jian , Hallett Michael , Han Ze-Guang , Al-Mahtab Mamun , Akbar Sheikh Mohammad Fazle , Khan Wasif Ali , Raqib Rubhana , Tanvir Imrana , Khan Haseeb Ahmed , Rabbani Shafaat A. , Szyf Moshe
Published: April 2023

PDF file - 116KB
Figure-S3 from ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
Authors: Huang Hsuan-Ying , Wu Wen-Ren , Wang Yu-Hui , Wang Jun-Wen , Fang Fu-Min , Tsai Jen-Wei , Li Shau-Hsuan , Hung Hsiao-Chin , Yu Shih-Chen , Lan Jui , Shiue Yow-Ling , Hsing Chung-His , Chen Li-Tzong , Li Chien-Feng
Published: April 2023

Figure-S3 PDF file 74K, Figure-S3 Validation of anti-angiogenic mediators and anti-proliferative fucntion of ASS1: (A) ELISA assay to measure secreted protein concentration in the conditioned media of ASS1-reexpressing versus control transfectants of myxofibrosarcoma. (a) The histogram shows statistically significantly decreased protein concentration of MMP-9 in ASS1-reexpressing group, which is a consistent phenomenon in all three cell lines. (b) By contrast, this finding of lowered concentration in the ASS1-reexpressing group was not corroborated for other proteins analyzed. For instance, CXCL10 only displays decreased concentration in the conditioned medium of ASS1-reexpressing NMFH-2 cells, unlike the results of corresponding Western blotting assays for cell lysates seen in Figure-5B. Experiments are performed in triplicate and results expressed as mean �} SD. (B) ASS1 reexpression abolishes cell proliferative activity of myxofibrosarcoma cells. By using an ELISA-based, colorimetric assay to assess the rate of BrdU uptake, cell proliferation is significantly reduced in stable ASS1-transfected NMFH-1 (left upper), OH931 (right upper), and NMFH-2 (left lower) cell lines compared to the corresponding empty controls. In addition, the cell number is significantly decreased in NMFH-2 cells stably transfected with the ASS1-expressing plasmid as detected in a real-time manner by using ECIS technique (right lower)
Supplementary Movie 1A from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Authors: Baek Sora , Choi Chang-Min , Ahn Sei Hyun , Lee Jong Won , Gong Gyungyub , Ryu Jin-Sook , Oh Seung Jun , Bacher-Stier Claudia , Fels Lüder , Koglin Norman , Hultsch Christina , Schatz Christoph A. , Dinkelborg Ludger M. , Mittra Erik S. , Gambhir Sanjiv S. , Moon Dae Hyuk
Published: April 2023

AVI, 167K, Maximum intensity projection of 18FFDG in a lung cancer patient (Patient 2).
Supplementary Figure 2 from Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy
Authors: Gold Kathryn A. , Kim Edward S. , Liu Diane D. , Yuan Ping , Behrens Carmen , Solis Luisa M. , Kadara Humam , Rice David C. , Wistuba Ignacio I. , Swisher Stephen G. , Hofstetter Wayne L. , Lee J. Jack , Hong Waun K.
Published: April 2023

PDF file - 63K, Calibration curves for RFS and OS.
Supplementary Table 5 from Relationship of Mammographic Density and Gene Expression: Analysis of Normal Breast Tissue Surrounding Breast Cancer
Authors: Sun Xuezheng , Gierach Gretchen L. , Sandhu Rupninder , Williams Tyisha , Midkiff Bentley R. , Lissowska Jolanta , Wesolowska Ewa , Boyd Norman F. , Johnson Nicole B. , Figueroa Jonine D. , Sherman Mark E. , Troester Melissa A.
Published: April 2023

Supplementary Table 5 - PDF file 46K, Clinicopathologic characteristics by the Active/Inactive extratumoral microenvironment subtype
Supplementary Figure 3 from Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Authors: Bossi Paolo , Bergamini Cristiana , Siano Marco , Cossu Rocca Maria , Sponghini Andrea P. , Favales Federica , Giannoccaro Marco , Marchesi Edoardo , Cortelazzi Barbara , Perrone Federica , Pilotti Silvana , Locati Laura D. , Licitra Lisa , Canevari Silvana , De Cecco Loris
Published: April 2023

FigS3: Biasogram representing the influence of tissue origin on outcome. Y axes indicate the outcome vector (long- versus short- PFS), while B indicates the nuisance variable (tissue origin; primary versus recurrence/metastatic). The colorgram represents a bivariate histogram of all the 17,378 detected genes; the green circles indicate the genes present in our signature.
Suppl Fig S2 from Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Authors: Suryawanshi Swati , Huang Xin , Elishaev Esther , Budiu Raluca A. , Zhang Lixin , Kim SungHwan , Donnellan Nicole , Mantia-Smaldone Gina , Ma Tianzhou , Tseng George , Lee Ted , Mansuria Suketu , Edwards Robert P. , Vlad Anda M.
Published: April 2023

Suppl Fig S2. Kras and Pten pathways in relationship to complement gene expression
Data Supplement from Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study
Authors: Xicola Rosa M. , Gagnon Molly , Clark Julia R. , Carroll Timothy , Gao Weihua , Fernandez Christian , Mijic Dragana , Rawson James B. , Janoski Ashley , Pusatcioglu Cenk K. , Rajaram Priyanka , Gluskin Adam B. , Regan Maureen , Chaudhry Vivek , Abcarian Herand , Blumetti Jennifer , Cintron Jose , Melson Joshua , Xie Hui , Guzman Grace , Emmadi Rajyasree , Alagiozian-Angelova Victoria , Kupfer Sonia S. , Braunschweig Carol , Ellis Nathan A. , Llor Xavier
Published: April 2023

Supplementary Table 1: Cook County CRC data extracted from the Illinois State Cancer Registry (ISCR) comparing periods 1996-2000 to 2006-2010 for both AAs and NHWs. (A) age at diagnosis; and (B) cancer stage at diagnosis
Supplementary Figure S6 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Authors: Lee Yunqin , Shin June Ho , Longmire Michelle , Wang Hua , Kohrt Holbrook E. , Chang Howard Y. , Sunwoo John B.
Published: April 2023

Supplementary Figure S6. CD44+ SCCHN cells have higher IFNÃŽÂ³R1 expression.
Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Authors: Gupta Shiv K. , Mladek Ann C. , Carlson Brett L. , Boakye-Agyeman Felix , Bakken Katrina K. , Kizilbash Sani H. , Schroeder Mark A. , Reid Joel , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S4. Dose dependent increase in cytotoxic effects of veliparib, TMZ or their combination in multiple PDX GBM models of differential TMZ sensitivity
Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Authors: Gupta Shiv K. , Mladek Ann C. , Carlson Brett L. , Boakye-Agyeman Felix , Bakken Katrina K. , Kizilbash Sani H. , Schroeder Mark A. , Reid Joel , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S5. Effects of Veliparib on TMZ induced DNA damage signaling in undifferentiated or differentiated GBM12 cells
Supplemental Tables S1-S7 from Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Authors: Chang Te-Sheng , Wu Yu-Chih , Chi Ching-Chi , Su Wei-Chi , Chang Pey-Jium , Lee Kam-Fai , Tung Tao-Hsin , Wang Jui , Liu Jun-Jen , Tung Shui-Yi , Kuo Liang-Mou , Ho Hong-Nerng , Ling Thai-Yen , Huang Yen-Hua
Published: April 2023

Supplemental Tables S1-S7. Table S1. Response to Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). Table S2. High expression of all three genes of OCT4, NANOG and IGF-IR was significantly associated with a higher proportion of subjects with hepatitis B, TNM stage, microvascular invasion and satellite nodules as well as a lower proportion of subjects with hepatitis C (N = 191). Table S3. Variables associated with early tumor recurrence after hepatectomy for HCC (N = 120). Table S4. Comparison of tumor formation incidence following the implantation of Hep3B HCC cells with PBS and IL-6 treatments of the implantation sites. Table S5. Associations of tumor formation with cell number and IL-6 treatment. Table S6. Real-time PCR primers and product size. Table S7. List of antibodies.
Supplementary Table S1 from First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Authors: Shapiro Geoffrey I. , Kwak Eunice , Dezube Bruce J. , Yule Murray , Ayrton John , Lyons John , Mahadevan Daruka
Published: April 2023

Supplementary Table S1. Summary of Dose Escalation on Twice-Weekly and Once-Weekly Regimens of AT13387
Supplementary Figure 1 from Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
Authors: Ok Chi Young , Li Ling , Xu-Monette Zijun Y. , Visco Carlo , Tzankov Alexander , Manyam Ganiraju C. , Montes-Moreno Santiago , Dybaer Karen , Chiu April , Orazi Attilio , Zu Youli , Bhagat Govind , Chen Jiayu , Richards Kristy L. , Hsi Eric D. , Choi William W. L. , van Krieken J. Han , Huh Jooryung , Ai Weiyun , Ponzoni Maurilio , Ferreri Andrés J.M. , Farnen John P. , Møller Michael B. , Bueso-Ramos Carlo E. , Miranda Roberto N. , Winter Jane N. , Piris Miguel A. , Medeiros L. Jeffrey , Young Ken H.
Published: April 2023

PDF file - 3781KB, Supplemental Figure 1. Morphologic subtypes of EBV+ DLBCL. A, E, I, and M. The monomorphic subtype is composed of monotonous sheets of large transformed B-cells. B, F, J and N. The polymorphic subtype, canonical large B-cell neoplasm variant contains high density of large neoplastic cells and scattered cells with HRS-like features. C, G, K and O. The polymorphic subtype, Hodgkin-like variant shows lower density of neoplastic cells with HRS-like features. D, H, L and P. The polymorphic subtype, lymphoproliferative disorder-like variant has low density of neoplastic cells without Hodgkin lymphoma-like features. By immunohistochemistry, the monomorphic variant had a GCB phenotype, but all 3 polymorphic variants showed non-GCB phenotype.
Supplementary Figure 5 from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Authors: Endo Makoto , Yamamoto Hidetaka , Setsu Nokitaka , Kohashi Kenichi , Takahashi Yusuke , Ishii Takeaki , Iida Kei-ichiro , Matsumoto Yoshihiro , Hakozaki Michiyuki , Aoki Mikiko , Iwasaki Hiroshi , Dobashi Yoh , Nishiyama Kenichi , Iwamoto Yukihide , Oda Yoshinao
Published: April 2023

PDF file - 3331K, Representative examples of Everolimus-induced change in the activation of the AKT/mTOR and MAPK pathways assessed by immunocytochemistry. Decreased p-S6RP and p-p70S6K expressions by Everolimus (30 nM, a dose achievable in humans by oral administration) are detected in the FU-SFT8611 and HS-Sch-2 cell lines. p-AKT, p-mTOR, p-MEK, and p-ERK1/2 expressions show no obvious effect of Everolimus administration. Note that Everolimus treatment decreases the number of viable cells.
Supplementary Figure 4 from SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein–Dependent Apoptotic Pathway
Authors: Ran Long-Kuan , Chen Yong , Zhang Zhen-Zhen , Tao Na-Na , Ren Ji-Hua , Zhou Li , Tang Hua , Chen Xiang , Chen Ke , Li Wan-Yu , Huang Ai-Long , Chen Juan
Published: April 2023

SIRT6 regulates cell apoptosis via Bax signaling. mRNA microarray analysis indicated alternations in several key regulators in the Bax-mediated apoptotic pathway. *, p<0.01.
Supplementary Figure 5 from Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9
Authors: Lu Mei-Hsuan , Huang Chao-Cheng , Pan Mei-Ren , Chen Hong-Hwa , Hung Wen-Chun
Published: April 2023

PDF file - 65K, Pre-miR-negative control
Supplemental Table 2 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Authors: Reiss Kim A. , Herman Joseph M. , Zahurak Marianna , Brade Anthony , Dawson Laura A. , Scardina Angela , Joffe Caitlin , Petito Emily , Hacker-Prietz Amy , Kinders Robert J. , Wang Lihua , Chen Alice , Temkin Sarah , Horiba Naomi , Siu Lillian L. , Azad Nilofer S.
Published: April 2023

Sites of disease and progression of all patients.
Supplementary Figure 1 from Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Authors: Peeters Marc , Oliner Kelly S. , Parker Alex , Siena Salvatore , Van Cutsem Eric , Huang Jing , Humblet Yves , Van Laethem Jean-Luc , André Thierry , Wiezorek Jeffrey , Reese David , Patterson Scott D.
Published: April 2023

PDF file - 57K, Summary of tumor response and tumor genotype among patients who received treatment with panitumuab plus BSC or BSC alone in either the randomized phase 3 study or the extension and who had multigene sequencing information available. For all patients enrolled, tumor response was based on investigator assessment. BSC, best supportive care.
Supplementary Figure S3 from G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients
Authors: Broselid Stefan , Cheng Benxu , Sjöström Martin , Lövgren Kristina , Klug-De Santiago Heather L.P. , Belting Mattias , Jirström Karin , Malmström Per , Olde Björn , Bendahl Pär-Ola , Hartman Linda , Fernö Mårten , Leeb-Lundberg L.M. Fredrik
Published: April 2023

Representative histograms of MCF7 and MCF7-shGPER1 cell cycle distribution as determined by propidium iodide staining of DNA content and flow cytometry. Cells were treated without (grey) and with 1 μM G1 (clear) for 24 hr before analysis.
Supplementary Tables S1-5 and Figure S1 from Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival
Authors: Smith Christopher G. , Fisher David , Harris Rebecca , Maughan Timothy S. , Phipps Amanda I. , Richman Susan , Seymour Matthew , Tomlinson Ian , Rosmarin Dan , Kerr David , Chan Andrew T. , Peters Ulrike , Newcomb Polly A. , Idziaszczyk Shelley , West Hannah , Meade Angela , Kaplan Richard , Cheadle Jeremy P.
Published: April 2023

Supplementary Tables S1-5 and Figure S1. Supplementary Table S1 - Multivariate model of overall survival including known prognostic factors; Supplementary Table S2 - Univariate analyses of survival in our validation phase; Supplementary Table S3: Gene-dose effect for rs9929218; Supplementary Table S4 - Distribution of rs9929218 genotype by disease stage; Supplementary Table S5 - Univariate analysis of rs9929218 on overall survival according to COIN trial arm; Supplementary Figure S1 - The effect of rs9929218 on survival from the time of diagnosis to death.
Figure-S3 from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

Figure-S3 AMACR expression has no effect on migration/invasion of myxofibrosarcoma cells. In NMFH-1 (upper) and NMFH-2 (lower) cell lines with shAMACR, the capabilities of wound closure (A) and cell invasiveness (B) are not significantly impaired, compared with controls. Experiments are performed in triplicate and results expressed as mean {plus minus} SD.
Supplementary Methods, Supplementary Figure 1-8, Supplementary Table 1 from The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Authors: Ruella Marco , Kenderian Saad S. , Shestova Olga , Fraietta Joseph A. , Qayyum Sohail , Zhang Qian , Maus Marcela V. , Liu Xiaobin , Nunez-Cruz Selene , Klichinsky Michael , Kawalekar Omkar U. , Milone Michael , Lacey Simon F. , Mato Anthony , Schuster Stephen J. , Kalos Michael , June Carl H. , Gill Saar , Wasik Mariusz A.
Published: April 2023

Supplementary Methods: Fluorescence in situ hybridization (FISH); MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) enzymatic conversion assay; Western blot analysis; Multiparametric flow cytometry; Table S1. List of the antibodies used for multiparametric flow cytometry; Degranulation assay; Proliferation assay; Cytotoxicity assays; Cytokine measurements; Animal experiments; Figure S1. Different sensitivity to ibrutinib in hematological cell lines; Figure S2. MCL-RL engrafted mice: tumor burden and histology; Figure S3. CTL019 design and production; Figure S4. CTL019 cell production from primary MCL samples; Figure S5. Effect of ibrutinib in T cell function in vitro and in vivo; Figure S5. Effect of ibrutinib in T cell function in vitro and in vivo. A. CTL019 proliferation assay in the presence of ibrutinib;Figure S6. Peripheral blood T cell subsets in mice treated with CART19 or CART19-ibrutinib; Figure S7. CXCR4 and inhibitory/costimulatory receptor expression in peripheral blood of mice treated with CART19 or CART19-ibrutinib; Figure S8. A. Ibrutinib did not enhance the anti-tumor activity of control untransduced T cells.
Supplementary Figure S2 from Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Authors: Sharkey Robert M. , McBride William J. , Cardillo Thomas M. , Govindan Serengulam V. , Wang Yang , Rossi Edmund A. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

In vitro stability of IMMU-132 in mouse serum and measurement of IMMU-132 clearance from mouse serum, with PK parameters.
Supplementary Figure 6 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 177KB, JUNB and PLK1 are heterogeneously expressed in CTCL lesional skin, normal skin and benign inflammatory dermatoses skin samples.
Figure S3 from ABO Blood Group IgM Isoagglutinins Interact with Tumor-Associated O-Glycan Structures in Pancreatic Cancer
Authors: Hofmann Bianca T. , Stehr Anne , Dohrmann Thorsten , Güngör Cenap , Herich Lena , Hiller Jens , Harder Sönke , Ewald Florian , Gebauer Florian , Tachezy Michael , Precht Clarissa , Izbicki Jakob R. , Bockhorn Maximilian , Wagener Christoph , Wolters-Eisfeld Gerrit
Published: April 2023

Supplement Figures S3 A-D: Quantification of total IgM for blood group O, A, B and AB. A: Total IgM levels from samples of blood group O were analyzed for 19 PDAC patients and 21 healthy controls. B: Total IgM levels from samples of blood group A were analyzed for 19 PDAC patients and 21 healthy controls. C: Total IgM levels from samples of blood group B were analyzed for 13 PDAC patients and 18 healthy controls. D: Total IgM levels from samples of blood group AB were analyzed for 7 PDAC patients and 11 healthy controls.
Supplementary Figure S2 from T-Cell Levels Are Prognostic in Mantle Cell Lymphoma
Authors: Nygren Lina , Wasik Agata M. , Baumgartner-Wennerholm Stefanie , Jeppsson-Ahlberg Åsa , Klimkowska Monika , Andersson Patrik , Buhrkuhl Daren , Christensson Birger , Kimby Eva , Wahlin Björn E. , Sander Birgitta
Published: April 2023

Supplementary Figure S2. Median survival of patients treated with high dose chemotherapy and ASCT as first line treatment (n=38) was not reached. Median OS for all other patients (n=115) was 3.2 years (p<0.00005). Median survival of patients <70 years of age at diagnosis (n=82) was 8.1 years) and for patients >=70 years (n=71) was 2.3 years (p<0.00005). Median survival according to tumor cell proliferation in diagnostic lymph nodes. Cases were subgrouped in tertiles with 41 patients in the group with lowest proliferation (<15%), 43 patients with tumor cell proliferation 15-40% and 44 patients in the group with highest proliferation (>40%). In the first group the median OS was 6.0 years, in the middle group 4.1 years and in the group with highest proliferation OS was 2.3 years (p=0.0002).
Supplemental Table 2 from The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
Authors: Deng Changchun , Lipstein Mark , Rodriguez Richard , Serrano Xavier O. Jirau , McIntosh Christine , Tsai Wei-Yann , Wasmuth Andrew S. , Jaken Susan , O'Connor Owen A.
Published: April 2023

Supplemental Table 2. Representative synergy index of LY2409881 with lymphoma active drugs.
Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Authors: Besse Benjamin , Le Moulec Sylvestre , Mazières Julien , Senellart Hélène , Barlesi Fabrice , Chouaid Christos , Dansin Eric , Bérard Henri , Falchero Lionel , Gervais Radj , Robinet Gilles , Ruppert Anne-Marie , Schott Roland , Léna Hervé , Clément-Duchêne Christelle , Quantin Xavier , Souquet Pierre Jean , Trédaniel Jean , Moro-Sibilot Denis , Pérol Maurice , Madroszyk Anne-Catherine , Soria Jean-Charles
Published: April 2023

Appendix Methods and Materials, Tables 1-4, Figures 1-3. Appendix Table 1: Characteristics of patients at baseline Appendix Table 2: Best response rates for primary tumors and metastases in 24 patients treated with second-line bevacizumab plus erlotinib Appendix Table 3: PFS, OS, and response rates according to EGFR mutation status in 24 patients treated with second-line bevacizumab plus erlotinib Appendix Table 4: Overview of AEs in 24 patients treated with second-line bevacizumab plus erlotinib Appendix Figure 1. Response rates for patients treated with second-line bevacizumab plus erlotinib. Appendix Figure 2. Waterfall plots of best overall response for patients treated with second-line bevacizumab plus erlotinib. Appendix Figure 3. Kaplan-Meier curves for second-line treatment with bevacizumab plus erlotinib.
Supplementary Figure Legend, Tables 1 - 6 from MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation
Authors: Wermke Martin , Schmidt Anne , Middeke Jan Moritz , Sockel Katja , von Bonin Malte , Schönefeldt Claudia , Mair Sabine , Plodeck Verena , Laniado Michael , Weiss Günter , Schetelig Johannes , Ehninger Gerhard , Theurl Igor , Bornhäuser Martin , Platzbecker Uwe
Published: April 2023

PDF file - 103K, Contains supplementary tables S1 - S6 and legends for supplementary figures Supplementary table S1. Impact of pre-transplant variables on the cumulative incidence of relapse one year after transplantation. The cumulative incidences are given with 95% confidence intervals. Supplementary table S2. Causes of Non-replapse mortality. Absolute numbers and percentages in the respective LIC group are given. GvHD - Graft-versus-Host-Disease. Supplementary table S3. Multivariate competing risk regression analysis assessing serum ferritin in the context of other risk factors for NRM. Supplementary table S4. Multivariate competing risk regression analysis assessing transfusion burden in the context of other risk factors for NRM. Supplementary table S5. Multivariate Cox-regression analysis of overall survival including serum ferritin instead of LIC. Supplementary table S6. Multivariate Cox-regression analysis of overall survival including transfusion burden instead of LIC.
Supplementary Figure 3 from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 4 MB, (A) Reduced expression of BRD2, BRD3, BRD4 following expression of corresponding shRNA sequences was determined by qRT-PCR in T4302 CD133+ cells. Cell growth was measured for 5 days following knockdown of (B) BRD2, (C) BRD3, or (D) BRD4 in T4302 CD133+ cells as described in Figure 2A.
Supplementary Fig. S1 from Global Transcriptional Changes Following Statin Treatment in Breast Cancer
Authors: Bjarnadottir Olöf , Kimbung Siker , Johansson Ida , Veerla Srinivas , Jönsson Mats , Bendahl Pär-Ola , Grabau Dorthe , Hedenfalk Ingrid , Borgquist Signe
Published: April 2023

Supplementary Fig. S1. Flowchart of patients included in the trial and the data analyses conducted.
Supplementary Data from Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
Authors: Song Gina , Darr David B. , Santos Charlene M. , Ross Mark , Valdivia Alain , Jordan Jamie L. , Midkiff Bentley R. , Cohen Stephanie , Nikolaishvili-Feinberg Nana , Miller C. Ryan , Tarrant Teresa K. , Rogers Arlin B. , Dudley Andrew C. , Perou Charles M. , Zamboni William C.
Published: April 2023

Supplementary Data. Table S1. Product information from FormuMax Scientific, Inc. Table S2. Doxorubicin AUC0-96h in plasma, tissues, and tumor in the C3-TAg model and the T11 model after PLD or NL-doxo administration at 6 mg/kg I.V. x 1 via tail vein Table S3. Baseline and total influx of F4/80+ TAMs in the C3-TAg model and the T11 model after PLD or NL-doxo administration at 6 mg/kg I.V. x 1 via tail vein
Supplementary Table 1 and Figure 1 from Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium
Authors: Chen Chen , Duckworth Carrie A. , Zhao Qicheng , Pritchard David Mark , Rhodes Jonathan M. , Yu Lu-Gang
Published: April 2023

PDF file - 106K, Table S1: Characteristics of the colorectal cancer patients; Fig S1: Effect of low and high galectin-3-containing human serum on cytokine secretion from HMVECs.
Supplementary Figure 2 from Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
Authors: Kalota Anna , Jeschke Grace R. , Carroll Martin , Hexner Elizabeth O.
Published: April 2023

PDF file - 22K, Supplementary Figure S2: Level of mutant JAK2 V617F allele frequency in patient granulocytes does not correlate with response to inhibition of phosphoSTAT5.
Figure S4 from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

SH3GL2 depletion in BCa cells.
Supplementary Figure 1 from Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients
Authors: Mayerhoefer Marius E. , Karanikas Georgios , Kletter Kurt , Prosch Helmut , Kiesewetter Barbara , Skrabs Cathrin , Porpaczy Edit , Weber Michael , Pinker-Domenig Katja , Berzaczy Dominik , Hoffmann Martha , Sillaber Christian , Jaeger Ulrich , Müllauer Leonhard , Simonitsch-Klupp Ingrid , Dolak Werner , Gaiger Alexander , Ubl Philipp , Lukas Julius , Raderer Markus
Published: April 2023

PDF file - 388KB, A 63 year-old male patient with a histologically verified MALT lymphoma of the stomach (light blue arrows) and the left parotid gland (light blue arrowheads). The parotid lesion shows only a very faint tracer uptake on 18F-FDG-PET and the fused color-coded PET/CT that was interpreted as physiological muscle uptake by one rater and as mild inflammation of the gland by the other rater. On CE-CT, where the lesion was missed by both raters, the left parotid gland appears only slightly larger than the right gland, and there are some uncharacteristic calcifications. However, no lesion can be delineated. On DWI and fused color-coded DWI-MRI, the lesion shows a very high, clearly abnormally high signal, indicative of strong diffusion restriction (high cellular density). The thickened gastric wall shows no abnormal tracer uptake on PET and PET/CT and is unspecific on CE-CT, whereas it shows an abnormally high signal on DWI and DWI-MRI, in good accordance with the histologically verified lymphoma. Note: the homogeneous high signal of the spleen on DWI(-MRI) is physiological.
Supplementary Figure 3 from Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
Authors: Wang Don-Hong , Lee Hyun-Sung , Yoon David , Berry Gerald , Wheeler Thomas M. , Sugarbaker David J. , Kheradmand Farrah , Engleman Edgar , Burt Bryan M.
Published: April 2023

CD45-humanEGFR+ cells were sorted from the lungs of bitransgenic mice fed dox for 7 weeks and cultured for 24 hours in the presence of empty liposomes or clodronate-liposomes. Flow cytometry was used to evaluate cell death (DAPI) and apoptosis (Annexin V).
Supplementary Figure 2 from Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
Authors: Wang Don-Hong , Lee Hyun-Sung , Yoon David , Berry Gerald , Wheeler Thomas M. , Sugarbaker David J. , Kheradmand Farrah , Engleman Edgar , Burt Bryan M.
Published: April 2023

Bitransgenic mice were fed dox for 7 weeks and treated with a depleting antibody against CSF-1R every other day. Expression of MHC-II and CD40 were evaluated by flow cytometry (A) and tumor burden was evaluated by H-E staining on lung tissue sections (B).
Supplementary Figure 1 from Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
Authors: Wang Don-Hong , Lee Hyun-Sung , Yoon David , Berry Gerald , Wheeler Thomas M. , Sugarbaker David J. , Kheradmand Farrah , Engleman Edgar , Burt Bryan M.
Published: April 2023

(A) Flow cytometry was used to determine the expression of human EGFR on AM and CD45- cells within single cell suspensions of lung cells from bitransgenic mice fed dox for 7 weeks.
Supplemental Methods from Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Authors: Wellbrock Jasmin , Latuske Emily , Köhler Julian , Wagner Katharina , Stamm Hauke , Vettorazzi Eik , Vohwinkel Gabi , Klokow Marianne , Uibeleisen Roswitha , Ehm Patrick , Riecken Kristoffer , Loges Sonja , Thol Felicitas , Schubert Claudia , Amling Michael , Jücker Manfred , Bokemeyer Carsten , Heuser Michael , Krauter Jürgen , Fiedler Walter
Published: April 2023

Supplemental Material and Methods
Supplementary Table S7 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Table S7. All Somatic Nonsynonymous Mutations Detected with Whole-Exome Sequencing in PCNSL cases.
Supplemental Table 3 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
Authors: Guin Sunny , Ru Yuanbin , Agarwal Neeraj , Lew Carolyn R. , Owens Charles , Comi Giacomo P. , Theodorescu Dan
Published: April 2023

Spearman correlations between AGL and HAS2 expression in localized (Ta/T1 and low grade) and advanced (T3/T4 and high grade) bladder cancer patient samples
Supplemental Table 1 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
Authors: Guin Sunny , Ru Yuanbin , Agarwal Neeraj , Lew Carolyn R. , Owens Charles , Comi Giacomo P. , Theodorescu Dan
Published: April 2023

List of all differentially regulated probes with AGL loss in UMUC3 bladder cancer cells at FDR at 2%.
Supplementary Table S1 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Table S1. Clinical annotations and survival data of the cohort analyzed in this study.
Supplementary Figure S5 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Authors: Silva Ines P. , Salhi Amel , Giles Keith M. , Vogelsang Matjaz , Han Sung W. , Ismaili Naima , Lui Kevin P. , Robinson Eric M. , Wilson Melissa A. , Shapiro Richard L. , Pavlick Anna , Zhong Judy , Kirchhoff Tomas , Osman Iman
Published: April 2023

Kaplan-Meier analysis shows no significant difference in overall survival of melanoma patients from the validation cohort based on KDR status (TA,AA: Q472H variant, TT: WT variant).
Table S2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

Correlation between CEA TCB response and genetic data
Supplementary Figure S3 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Authors: Silva Ines P. , Salhi Amel , Giles Keith M. , Vogelsang Matjaz , Han Sung W. , Ismaili Naima , Lui Kevin P. , Robinson Eric M. , Wilson Melissa A. , Shapiro Richard L. , Pavlick Anna , Zhong Judy , Kirchhoff Tomas , Osman Iman
Published: April 2023

Sequencing data of paired primary/metastatic tumor samples from two patients.
Supplementary Figure S2 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Authors: Silva Ines P. , Salhi Amel , Giles Keith M. , Vogelsang Matjaz , Han Sung W. , Ismaili Naima , Lui Kevin P. , Robinson Eric M. , Wilson Melissa A. , Shapiro Richard L. , Pavlick Anna , Zhong Judy , Kirchhoff Tomas , Osman Iman
Published: April 2023

Somatic mutations (top column) identified by Ion Torrent sequencing of the pilot melanoma cohort are listed for each patient (left hand column).
Supplemental Figure 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

Assessment of binding of CEA TCB to human and cynomolgus monkey CEA- and CD3-expressing cells, internalization and ADCC, CDC activity.
Supplementary Figure Legends from Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Authors: Hedayati Mohammad , Haffner Michael C. , Coulter Jonathan B. , Raval Raju R. , Zhang Yonggang , Zhou Haoming , Mian Omar , Knight Emma J. , Razavi Nina , Dalrymple Susan , Isaacs John T. , Santos Aileen , Hales Russell , Nelson William G. , Yegnasubramanian Srinivasan , DeWeese Theodore L.
Published: April 2023

Legend for Supplementary Files 1-4
Supplementary Figure 4 from Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Authors: Hedayati Mohammad , Haffner Michael C. , Coulter Jonathan B. , Raval Raju R. , Zhang Yonggang , Zhou Haoming , Mian Omar , Knight Emma J. , Razavi Nina , Dalrymple Susan , Isaacs John T. , Santos Aileen , Hales Russell , Nelson William G. , Yegnasubramanian Srinivasan , DeWeese Theodore L.
Published: April 2023

IR reduced xenograft growth in intact mice without androgen modulation. Xenograft tumors of LAPC4 (A) and LNCaP (B) cells established in intact nude mice were exposed to sham (control) or 8Gy ionizing radiation (IR). Tumor size was longitudinally determined by caliper measurements. Graph shows relative tumor volumes normalized to the tumor size at the time of radiation.
Supplementary Figure 1 from Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Authors: Wilson Melissa A. , Zhao Fengmin , Letrero Richard , D'Andrea Kurt , Rimm David L. , Kirkwood John M. , Kluger Harriet M. , Lee Sandra J. , Schuchter Lynn M. , Flaherty Keith T. , Nathanson Katherine L.
Published: April 2023

PDF file - 156KB, Supplemental Figure 1. Kaplan-Meier estimates of overall survival (OS) for patients on ECOG 2603 with mutation data compared to patients on ECOG 2603 without mutation data. (A) OS for patients with and without mutation data, all treatment arms collapsed. (B) OS for patients with and without data, separated out based on treatment arms. Control, carboplatin/paclitaxel. Sorafenib, carboplatin/paclitaxel/sorafenib.
Supplemental Figure S5 from Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells
Authors: Nguyen Le Xuan Truong , Zhu Li , Lee Yunqin , Ta Lynn , Mitchell Beverly S.
Published: April 2023

Supplemental Figure S5. Colocalization of Ebp1 p48 and Pol I complex.
Supplemental Figure S3 from Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells
Authors: Nguyen Le Xuan Truong , Zhu Li , Lee Yunqin , Ta Lynn , Mitchell Beverly S.
Published: April 2023

Supplemental Figure S3. Relative expression of Ebp1 and rRNA synthesis in bone marrow cells from control and MLL-AF9 and MLL-AF10 mice.
Supplementary Table S1 from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

Clinicopathological features and correlation of TXNIP expression in PDAC
Supplementary Figure S2 from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

Function of TXNIP in pancreatic cancer glucose metabolism and proliferation
Supplementary Table 5 from Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival
Authors: Yap Kai Lee , Kiyotani Kazuma , Tamura Kenji , Antic Tatjana , Jang Miran , Montoya Magdeline , Campanile Alexa , Yew Poh Yin , Ganshert Cory , Fujioka Tomoaki , Steinberg Gary D. , O'Donnell Peter H. , Nakamura Yusuke
Published: April 2023

Genes calculated to be significantly mutated by Genome MuSic algorithm (p<0.01).